Table 2. Fondaparinux Phase III trials.... | American Society of Hematology

Table 2.

Fondaparinux Phase III trials.

Group	Study Name	Treatment	n	VTE^d	P	Major Bleeding	P
Abbreviations: DVT, deep venous thrombosis; NS, not significant; PE, pulmonary embolism; VTE, venous thromboembolism.
^a2.5 mg SC qd starting 6 hrs post-op
^b40 mg SC given 12 hours pre-op and then daily
^c30 mg SC q12h starting 12–24 hours post-op
^dVTE was determined by venography in prophylaxis studies.
^e7.5 mg SC qd
^fIV adjusted-dose
^g1 mg/kg SC q12h
Orthopedic Surgery Prophylaxis
Hip replacement	Ephesus¹	fondaparinux^a	908	4.1%	< .0001	4.1%
		enoxaparin^b	919	9.2%		2.8%	NS
Hip replacement	Pentathalon²	fondaparinux^a 1.0%	787	6.1%	NS	1.8%	NS
		enoxaparin^c	797	8.3%		1.0%
Hip fracture	Penthifra³	fondaparinux^a	626	8.3%	< .001	2.2%	NS
		enoxaparin^b	624	19.1%		2.3%
Knee replacement	Pentamarks⁴	fondaparinux^a	361	12.5%	< .001	2.1%	< .01
		enoxaparin^c	363	27.8%		0.2%
Hip fracture	Penthifra-Plus⁵	fondaparinux 7d^a		35.0%	< .001
		fondaparinux 28d^a		1.4%
Treatment of DVT and PE
Pulmonary embolism	Matisse PE⁶	fondaparinux^e	1103	3.8%	NS	1.3%	NS
		heparin^f	1110	5.0%		1.1%
Deep vein thrombosis	Matisse DVT⁶	fondaparinux^e	1098	3.9%	NS	1.1%	NS
		enoxaparin^g	1107	4.1%		1.2%

Group	Study Name	Treatment	n	VTE^d	P	Major Bleeding	P
Abbreviations: DVT, deep venous thrombosis; NS, not significant; PE, pulmonary embolism; VTE, venous thromboembolism.
^a2.5 mg SC qd starting 6 hrs post-op
^b40 mg SC given 12 hours pre-op and then daily
^c30 mg SC q12h starting 12–24 hours post-op
^dVTE was determined by venography in prophylaxis studies.
^e7.5 mg SC qd
^fIV adjusted-dose
^g1 mg/kg SC q12h
Orthopedic Surgery Prophylaxis
Hip replacement	Ephesus¹	fondaparinux^a	908	4.1%	< .0001	4.1%
		enoxaparin^b	919	9.2%		2.8%	NS
Hip replacement	Pentathalon²	fondaparinux^a 1.0%	787	6.1%	NS	1.8%	NS
		enoxaparin^c	797	8.3%		1.0%
Hip fracture	Penthifra³	fondaparinux^a	626	8.3%	< .001	2.2%	NS
		enoxaparin^b	624	19.1%		2.3%
Knee replacement	Pentamarks⁴	fondaparinux^a	361	12.5%	< .001	2.1%	< .01
		enoxaparin^c	363	27.8%		0.2%
Hip fracture	Penthifra-Plus⁵	fondaparinux 7d^a		35.0%	< .001
		fondaparinux 28d^a		1.4%
Treatment of DVT and PE
Pulmonary embolism	Matisse PE⁶	fondaparinux^e	1103	3.8%	NS	1.3%	NS
		heparin^f	1110	5.0%		1.1%
Deep vein thrombosis	Matisse DVT⁶	fondaparinux^e	1098	3.9%	NS	1.1%	NS
		enoxaparin^g	1107	4.1%		1.2%